Research / ARL / Fundamental state Inspectable configuration
State dimensions Filing 0001102238-22-000019 General Corporate
Debt relative to revenue 50th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.debt_to_revenue
2068.64% · OPTIONAL · VALID
Revenue growth 30th Own-history percentile · N=10
Evidence method Yoy · gp.fundamentals.revenue
-26.79% · CORE · VALID
Operating margin 33th Own-history percentile · N=15
Evidence method Level · gp.fundamentals.operating_margin
-37.31% · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 27 states Self-history eligible
Jun 30, 2021 3/4 normalized Level 3 Sep 30, 2021 4/4 normalized Level 3 Dec 31, 2021 4/4 normalized Level 3 Jun 30, 2022 3/3 normalized Level 3 Sep 30, 2022 4/4 normalized Level 3 Dec 31, 2022 4/4 normalized Level 3 Jun 30, 2023 4/4 normalized Level 3 Sep 30, 2023 4/4 normalized Level 3 Dec 31, 2023 4/4 normalized Level 3 Mar 31, 2024 4/4 normalized Level 3 Jun 30, 2024 4/4 normalized Level 3 Sep 30, 2024 4/4 normalized Level 3 Dec 31, 2024 4/4 normalized Level 3 Mar 31, 2025 4/4 normalized Level 3 Jun 30, 2025 4/4 normalized Level 3 Sep 30, 2025 4/4 normalized Level 3 Dec 31, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 4/4 normalized Level 3 Dec 31, 2025 4/4 normalized Amended as filed Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 2172.92%
Current 2068.64%
Delta -104.27% Profitability Increased
Previous -57.72%
Current -37.31%
Delta 20.41% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.